{"id":5248,"date":"2019-06-12T15:06:28","date_gmt":"2019-06-12T09:36:28","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5248"},"modified":"2025-05-06T12:43:25","modified_gmt":"2025-05-06T07:13:25","slug":"teplizumab-delays-the-progression-of-type-1-diabetes","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes","title":{"rendered":"Teplizumab delays the progression of Type 1 Diabetes"},"content":{"rendered":"\n

The study published in The New England Journal of Medicine<\/em> set out to study the effect of the drug teplizumab <\/strong>in people at high risk for type 1 diabetes. According to recent Phase II clinical trials, in experimental immunotherapy conducted, the drug has been able to delay the onset of disease for the first time in two years.  <\/p>\n\n\n\n

According to the American Diabetes Association, Type 1 diabetes is one of the most chronic diseases, affecting about 1.25 million people in the U.S. with nearly 18,000 new Type 1 Diabetes diagnosed cases annually in people under age 20. <\/p>\n\n\n\n

Diabetes usually begins a year before it is diagnosed. After the research that discovered the immune system as the culprit behind Type 1 Diabetes, the understanding of the disease, the fact that is an autoimmune disease and is prompted by the killing or damaging of insulin-producing beta cells by T cells in the pancreas, helped researchers to further study and enhance the Type1 Diabetes therapy market<\/strong>. This clinical trials, began 8 years ago, to test teplizumab, <\/strong>in which 76 candidates at potential risk of developing Type 1 Diabetes were tested, also supported the Among which, those who were given teplizumab <\/strong>showed a lower rate of becoming diabetic as compared to those given placebo. <\/p>\n\n\n\n

What Teplizumab <\/strong>does is, it reduces the risk of an attack of lymphocytes on beta cells, leading to low lymphocyte count thus preventing the development of Type 1 diabetes<\/a><\/strong>. Initially licensed to Eli liiy, at present, New Jersey-based Provention Bio holds the rights to the drug, trusting its potential to hamper immune attacks. Moreover, the company decided to advance the clinical trials of Teplizumab <\/strong>further to Phase III and conducting fresh studies on those found positive with autoantibodies. <\/p>\n","protected":false},"excerpt":{"rendered":"

The study published in The New England Journal of Medicine set out to study the effect of the drug teplizumab in people at high risk for type 1 diabetes. According to recent Phase II clinical trials, in experimental immunotherapy conducted, the drug has been able to delay the onset of disease for the first time in […]<\/p>\n","protected":false},"author":1,"featured_media":5249,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[812,17723,17724,4507,17722,1877],"industry":[17225],"therapeutic_areas":[17240],"class_list":["post-5248","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-diabetes","tag-diabetes-market","tag-diabetes-pipeline","tag-teplizumab","tag-type-1-diabetes","tag-type-1-diabetes-mellitus-t1dm","industry-pharmaceutical","therapeutic_areas-endocrinology-and-metabolic-disorders"],"acf":[],"yoast_head":"\nTeplizumab delays the progression of Type 1 Diabetes - DelveInsight<\/title>\n<meta name=\"description\" content=\"The study published in The New England Journal of Medicine set out to study the effect of the drug teplizumab in people at high...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Teplizumab delays the progression of Type 1 Diabetes - DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The study published in The New England Journal of Medicine set out to study the effect of the drug teplizumab in people at high...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-06-12T09:36:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-06T07:13:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09032309\/Type-1-Diabetes.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2168\" \/>\n\t<meta property=\"og:image:height\" content=\"1185\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Teplizumab delays the progression of Type 1 Diabetes - DelveInsight","description":"The study published in The New England Journal of Medicine set out to study the effect of the drug teplizumab in people at high...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes","og_locale":"en_US","og_type":"article","og_title":"Teplizumab delays the progression of Type 1 Diabetes - DelveInsight","og_description":"The study published in The New England Journal of Medicine set out to study the effect of the drug teplizumab in people at high...","og_url":"https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-06-12T09:36:28+00:00","article_modified_time":"2025-05-06T07:13:25+00:00","og_image":[{"width":2168,"height":1185,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09032309\/Type-1-Diabetes.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes","url":"https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes","name":"Teplizumab delays the progression of Type 1 Diabetes - DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09032309\/Type-1-Diabetes.png","datePublished":"2019-06-12T09:36:28+00:00","dateModified":"2025-05-06T07:13:25+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The study published in The New England Journal of Medicine set out to study the effect of the drug teplizumab in people at high...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/teplizumab-delays-the-progression-of-type-1-diabetes#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09032309\/Type-1-Diabetes.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09032309\/Type-1-Diabetes.png","width":2168,"height":1185,"caption":"Type 1 Diabetes"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/06\/09032309\/Type-1-Diabetes-300x164.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Diabetes Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Diabetes Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">teplizumab<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Type 1 Diabetes<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">type 1 diabetes mellitus (T1DM)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Diabetes<\/span>","<span class=\"advgb-post-tax-term\">Diabetes Market<\/span>","<span class=\"advgb-post-tax-term\">Diabetes Pipeline<\/span>","<span class=\"advgb-post-tax-term\">teplizumab<\/span>","<span class=\"advgb-post-tax-term\">Type 1 Diabetes<\/span>","<span class=\"advgb-post-tax-term\">type 1 diabetes mellitus (T1DM)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 1 year ago"},"absolute_dates":{"created":"Posted on Jun 12, 2019","modified":"Updated on May 6, 2025"},"absolute_dates_time":{"created":"Posted on Jun 12, 2019 3:06 pm","modified":"Updated on May 6, 2025 12:43 pm"},"featured_img_caption":"Type 1 Diabetes","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5248"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5248\/revisions"}],"predecessor-version":[{"id":31705,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5248\/revisions\/31705"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5249"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5248"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5248"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}